Table A1.
Prevalence and cumulative incidence of BPH/LUTS-related outcomes in the intervention arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
| Analysis of self-reported sexually transmitted infections
|
Analysis of serologically detected sexually transmitted infections
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prevalent analysis
|
Incident analysis
|
Prevalent analysis
|
Incident analysis
|
|||||||||
| No. of cases | No. of participants | Prevalence, % | No. of cases | No. of participants | Cumulative incidence, % | No. of cases | No. of participants | Prevalence, % | No. of cases | No. of participants | Cumulative incidence, % | |
| Physician diagnosis of an enlarged prostate/BPH | 7 254 | 32 900 | 22.1 | 1 552 | 5 226 | 29.7 | 276 | 1 144 | 24.1 | 62 | 165 | 37.6 |
| Nocturia* | 10 605 | 31 859 | 33.3 | 1 681 | 5 065 | 33.2 | 410 | 1 096 | 37.4 | 60 | 158 | 38.0 |
| BPH surgery | 1 041 | 32 900 | 3.2 | – | – | – | 48 | 1 144 | 4.2 | – | – | – |
| Finasteride use | – | – | – | 161 | 5 226 | 3.1 | – | – | – | 7 | 165 | 4.2 |
| DRE-estimated prostate volume ≥30 mL | 14 025 | 29 338 | 47.8 | 2 774 | 4 662 | 59.5 | 480 | 989 | 48.5 | 101 | 148 | 68.2 |
| PSA > 1.4 ng/mL | 12 554 | 31 838 | 39.4 | 1 469 | 5 206 | 28.2 | 451 | 1 096 | 41.2 | 58 | 165 | 35.2 |
| Evidence of LUTS and prostate enlargement | 10 486 | 32 794 | 32.0 | 1 861 | 5 221 | 35.6 | 414 | 1 136 | 36.4 | 71 | 165 | 43.0 |
*
Waking ≥2 times/night to urinate.